AT A GLANCE
ANZUP ANNUAL REPORT 2021
Chief Executive Officer’s Report In 2020, ENZAMET featured in ESMO’s Clinical Practice Guidelines for 2020. ENZAMET was also named in the ASCO Annual Report on Progress Against Cancer earlier in the year as one of its Clinical Cancer Advances for 2020. This ANZUPled trial also contributed to registration of the agent for this indication by the FDA in December 2019, and has been incorporated into US and European treatment guidelines.
What a year it has been! To say it has been a challenge is an understatement. We were looking forward to a new decade and rolling out another year of innovative ANZUP programs including conducting our high quality investigator initiated clinical trials, supporting the development of a pipeline of new concepts, hosting our annual scientific meeting (ASM) as well as our Below the Belt Pedalthon fundraising events, to name a few. Then came COVID-19, not only putting ANZUP’s plans into disarray, but the entire world. We rapidly needed to review, revise and repurpose almost everything we had planned including suspending our clinical trials as we implemented a number of strategies to ensure we met the objectives of the organisation. Despite this curve ball, ANZUP managed to hit some significant milestones throughout the year. Our ENZAMET clinical trial (ANZUP 1304) continued to have impact and be recognised worldwide. In 2019 the trial featured in the ASCO main plenary session, and these practice changing results continue to generate worldwide interest both through extensive media coverage and the medical community.
On 1 December 2020, ENAZMET scooped the pool at the ACTA Trial of the Year Awards Ceremony. ENZAMET was awarded the 2020 ACTA Trial of the Year Award, the ACTA STInG Award for Excellence in Trial Statistics and the Consumer Involvement Award. A fantastic achievement and the first trial to win all three awards! We acknowledge and thank the dedicated international team of researchers, staff, consumers, and most importantly, our trial participants. Another achievement was our TheraP trial (ANZUP 1603), featured as an oral presentation at the ASCO 2020 virtual meeting on Friday 29 May 2020, with Michael Hofman presenting the interim results. TheraP is the first randomised trial comparing 177Lu-PSMA-617 (Lu-PSMA), a novel radioactive treatment, to the current standard-of-care chemotherapy called cabazitaxel for men with metastatic castration-resistant prostate cancer. TheraP is a partnership between ANZUP and the Prostate Cancer Foundation of Australia (PCFA) with support from the Australian Nuclear Science and Technology Organisation (ANSTO), Endocyte Inc., a Novartis Company, Movember, The Distinguished Gentleman’s Ride, It’s a Bloke Thing and CAN4CANCER and the University of Sydney’s NHMRC Clinical Trials Centre providing central study coordination. We are very grateful to all the investigators, trial coordinators, patients and their families for their participation.
7
